Posted by Michael Wonder on 03 Nov 2020
Food and Drug Administration accepts BioMarin's new drug application for vosoritide to treat children with achondroplasia
2 November 2020 - If approved, first therapy in U.S. for the treatment of achondroplasia.
BioMarin today announced that the U.S. FDA has accepted the new drug application for vosoritide, an investigational, once daily injection analog of C type natriuretic peptide for children with achondroplasia, the most common form of disproportionate short stature in humans.
This acceptance by the FDA marks the first marketing application accepted for a treatment for achondroplasia in the United States.
